CAR-T Therapy Shows Promise in Lenalidomide-Refractory Multiple Myeloma
Key Insights
CARTITUDE-4 trial results show promise for patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy, indicating a potential new treatment option.
Five-year follow-up data from the TRANSCEND-NHL-001 trial were discussed, providing insights into the long-term efficacy and safety of CAR-T cell therapy in lymphoma.
Bendamustine was found to be an effective alternative to fludarabine for lymphodepletion in large B-cell lymphoma patients receiving CD19-directed CAR-T therapy, addressing fludarabine shortages.

Stay Updated with Our Daily Newsletter
Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.